Learning outcomes
By the end of this lesson you should be able to: define harmful use and dependence and apply the AUDIT and CAGE screens; recognise intoxication, withdrawal and dependence syndromes for alcohol, opioids, benzodiazepines and stimulants; describe the time course of alcohol withdrawal and the management of Wernicke encephalopathy, Korsakoff syndrome and delirium tremens; select the appropriate setting for alcohol detoxification and describe relapse-prevention pharmacotherapy; apply the specific knowledge of alcohol and drug substances needed for the acute management of intoxication and overdose; and describe opioid substitution therapy, harm reduction and the treatment of nicotine and stimulant dependence.
Prerequisites
Lessons 5 and 6 for the assessment framework and the multi-level aetiology of dependence, and Lesson 9 for the suicide risk assessment that coexists with every substance use disorder.
The big idea
The single most clinically relevant idea is that dependence is a disorder of regulation, not of character, and that the pharmacology is what makes it a medical problem. Alcohol and benzodiazepines act on the same GABA-A receptor, so their withdrawal syndromes are the only two that are reliably life-threatening. Opioids cause profound dependence with severe withdrawal but withdrawal is not the danger — overdose is, and naloxone and substitution therapy are the counter-measures. Stimulants produce dependence and a depressive crash, and antipsychotics treat their psychosis. Knowing the three pharmacologies is most of the assessment.
| Substance | Principal receptor and action | Intoxication syndrome | Withdrawal syndrome | Danger |
|---|---|---|---|---|
| Alcohol | GABA-A potentiation and NMDA receptor blockade, with dopaminergic reward | Disinhibition, slurred speech, ataxia, nystagmus, lethargy, stupor, coma, respiratory depression; hypoglycaemia | Tremor, sweating, tachycardia, insomnia and anxiety, hallucinations and seizures between six and 48 hours, and delirium tremens at 48-96 hours | Delirium tremens and Wernicke encephalopathy; both preventable |
| Benzodiazepines and Z-drugs | GABA-A potentiation at a different site from alcohol, with cross-tolerance | Same as alcohol — drowsiness, ataxia, dysarthria, respiratory depression, especially with opioids | Anxiety, tremor, insomnia, seizures, and delirium; protracted over weeks | Seizures and delirium; abrupt cessation is the error |
| Opioids (heroin, morphine, codeine) | Mu and kappa agonism | Miosis, respiratory depression, drowsiness, cold clammy skin, constipation | Rhinorrhoea, lacrimation, yawning, sweating, piloerection, dilated pupils, myalgia, abdominal cramps, vomiting, diarrhoea and craving — distressing but not life-threatening | Overdose; aspiration; HIV, hepatitis B and C and endocarditis |
| Stimulants (cocaine, amphetamines, methamphetamine, mephedrone) | Increased noradrenaline, dopamine and serotonin at synapses and increased release | Euphoria, hypervigilance, tachycardia, hypertension, mydriasis, hyperthermia, stereotypy; chest pain from cardiac ischaemia; psychosis with paranoid delusions | A crash with hypersomnia, increased appetite, dysphoria and intense craving | Overdose with cardiovascular collapse; psychosis; severe withdrawal depression and suicide risk |
| Cannabis | THC agonist, plus CBD in some preparations | Relaxation, conjunctival injection, tachycardia, slowed time perception, impaired coordination and memory | Irritability, insomnia, anxiety, tremor, decreased appetite — usually mild | Psychosis, especially high potency and early adolescent use; dependence |
| Nicotine | Nicotinic receptor agonism, with dopaminergic reward | Stimulation, with nausea in the untolerant | Irritability, anxiety, poor concentration, increased appetite | The dependence is near-universal and the mortality is the largest in the field |
Screening and the initial assessment
Every patient in every specialty should be screened, because alcohol misuse is common, frequently concealed, and the underlying cause of a large fraction of admissions. A brief intervention is part of the assessment, not a separate intervention at a later appointment.
| Instrument | Items and scoring | Interpretation |
|---|---|---|
| AUDIT | Ten items: consumption, drinking behaviour, dependence symptoms and alcohol-related problems; maximum 40 | A score of 8 or more in men and 6 or more in women indicates hazardous or harmful drinking; scores of 20 or more indicate probable dependence and warrant a specialist assessment |
| AUDIT-C | The first three consumption questions | A screen of four or more in men and three or more in women is positive, with high sensitivity and minimal burden |
| CAGE | Cut down, Annoyed, Guilty, Eye-opener | Two or more positive suggests dependence; it is quick for bedside use but is insensitive to hazardous use without dependence |
| CAGE-AID | The CAGE adapted to include drug use | A useful single-question extension in psychiatric and emergency practice |
| SADQ | A 20-item self-rated severity of dependence | For quantifying severity in established dependence and for monitoring |
| CIWA-Ar | A clinician-rated 10-item withdrawal severity score | For symptom-triggered benzodiazepine regimens; it is a monitoring tool, not a diagnostic one |
A history should establish the amount and pattern of alcohol or drug use, the age of onset, the duration, the longest period of abstinence and how it was achieved, previous treatment, previous seizures or delirium tremens, and the existence of social or occupational consequences, criminal charges and relationship breakdown. Do not forget that liver disease, injection practice, psychiatric comorbidity and physical comorbidity determine most of the mortality of dependence, and that most deaths in patients with alcohol dependence are from causes other than withdrawal.
NoteA standard UK drink is 8 grams of alcohol, a US standard drink 14 grams; a 50 ml measure of spirits at 40 percent, half a pint of ordinary beer and a 175 ml glass of wine at 13 percent each contain roughly one unit. Low-risk drinking guidance in the UK is no more than 14 units a week for both sexes, spread across three or more days. The purpose of stating it precisely is to prevent the common error of counting glasses, bottles or cans rather than units.
Alcohol withdrawal and its complications
| Phase | Timing | Clinical features | Management |
|---|---|---|---|
| Early withdrawal | 6-12 hours | Tremor, anxiety, sweating, tachycardia, hypertension, insomnia, nausea, depression of mood | Thiamine (Pabrinex), fluids, and a benzodiazepine regimen or symptom-triggered treatment with monitoring of symptoms and observations |
| Alcohol withdrawal seizures | 12-48 hours | Generalised tonic-clonic seizures, usually one or two within a short period; rare status | Benzodiazepines are the treatment of choice; treat as seizures, and exclude hypoglycaemia, head injury and epilepsy |
| Hallucinations | 12-48 hours | Visual, occasionally auditory or tactile, with a clear sensorium and partial insight in some | The same benzodiazepine regimen, with reassurance about the nature of the experience |
| Delirium tremens | 48-96 hours | Profound agitation, confusion, disorientation, paranoid delusions, hallucinations, gross tremor, pyrexia, tachycardia, hypertension, dehydration — a medical emergency with significant mortality | High-dose benzodiazepine, intravenous fluids, parenteral thiamine, correction of electrolytes including magnesium, and admission to a medical or intensive care setting |
| Wernicke encephalopathy | Onset over days; in chronic deficiency at any time | The classic triad is confusion, ataxia and ophthalmoplegia, but a minority show all three; the commonest presentation is a confused, ataxic patient who may deteriorate while being sedated for something else | Immediate parenteral thiamine (Pabrinex) before any glucose load; under-treatment is the common error |
| Korsakoff syndrome | After Wernicke encephalopathy if untreated | Profound anterograde amnesia with confabulation and often a preserved social manner; the prognosis is poor | Prevention by treating Wernicke promptly; long-term care and thiamine continuation |
Watch outThiamine before glucose. In the acutely intoxicated, malnourished, confused patient, give parenteral thiamine first (or with the glucose), because a glucose load accelerates the consumption of thiamine and can precipitate Wernicke encephalopathy. Correct magnesium too, because hypomagnesaemia renders thiamine ineffective, and remember that parenteral thiamine is poorly replaced by oral thiamine in an acute episode.
Alcohol detoxification aims to manage withdrawal safely rather than to produce abstinence. For a patient with a modest dependence and no history of seizures or delirium tremens, a community detoxification reduces dose over seven to ten days. For a patient with a history of withdrawal seizures or delirium tremens, with significant medical or psychiatric comorbidity, with pregnancy, with homelessness, with polydrug use, or with a previous failed community attempt, inpatient detoxification is required. Chlordiazepoxide is the standard agent; in hepatic failure or severe respiratory disease, lorazepam or oxazepam is used, as they are not metabolised by oxidation in the liver.
Detoxification and relapse prevention
Relapse rates after unassisted abstinence are high; combining pharmacotherapy with psychosocial intervention roughly doubles abstinence rates, and the medication choice is made on the patient's goal and comorbidity.
| Medication | Mechanism and goal | Practical points | Side effects |
|---|---|---|---|
| Acamprosate | Modulates glutamatergic transmission, and reduces the 'need to drink' through the NMDA system; supports abstinence | Started at the beginning of detoxification or at abstinence, and continued for six months; contraindicated in severe renal impairment and pregnancy | Diarrhoea; the profile is benign |
| Naltrexone | Mu-opioid receptor antagonist; reduces the rewarding effect of alcohol and the craving to drink; can be started while the patient is still drinking | Can be given orally daily or as a monthly intramuscular injection; use cautiously if opioids may be given for pain, because it will precipitate withdrawal and block analgesia | Nausea, headache; contraindicated in current opioid use and in acute hepatitis |
| Disulfiram | Inhibits aldehyde dehydrogenase, so that drinking while taking it causes a flushing reaction with vomiting and headache; a deterrent requiring supervised administration | Effective only with commitment and supervision; requires abstinence, informed consent, and a card carried in case of emergency | Rash, metallic taste, neuropathy, hepatotoxicity, and the risk of the reaction itself if the patient drinks regardless |
| Baclofen | GABA-B agonist with some evidence for reducing craving | Second-line in many countries; requires renal and hepatic caution | Sedation, and abrupt discontinuation can cause a withdrawal-like syndrome |
NotePharmacotherapy only works alongside psychosocial work: motivational interviewing, cognitive therapy, family involvement, community reinforcement, and mutual-aid groups such as Alcoholics Anonymous. The strongest predictor of outcome is engagement, which is why the first appointment's substance is the offering of a specific, small, achievable step rather than a demand for lifelong abstinence.
Opioid dependence
Opioid dependence is a chronic relapsing condition with a high mortality, and the two pillars of treatment are opioid substitution therapy and harm reduction. Methadone (full agonist) and buprenorphine (partial agonist, safer in overdose, available sublingually) reduce illicit opioid use, mortality, HIV and hepatitis C transmission and criminal activity, and are the only treatments shown to reduce mortality.
| Feature | Opioid intoxication | Opioid overdose | Opioid withdrawal |
|---|---|---|---|
| Clinical picture | Miosis, drowsiness, euphoria, slowed respiration, constricted pupils, hyporeflexia | Respiratory depression, pinpoint pupils, loss of consciousness, cyanosis, apnoea | Rhinorrhoea, lacrimation, yawning, mydriasis, piloerection, myalgia, vomiting, diarrhoea, abdominal cramps, insomnia, intense craving |
| Urgency | Monitor | Medical emergency | Distressing, not life-threatening |
| Treatment | Supportive care | Airway and ventilation; naloxone 400-800 micrograms intravenously, repeated as needed, intramuscularly or intranasally where intravenous access is unavailable; watch for re-sedation because naloxone has a shorter half-life than most opioids | Agonist substitution with methadone or buprenorphine, or symptomatic treatment with clonidine, antiemetics and antidiarrhoeals |
Watch outNaloxone is competitive, so giving the full dose to an opioid-dependent patient can precipitate acute withdrawal. Titrate to respiratory effort, not to consciousness, in patients who are dependent, and remember that the half-life is 30-90 minutes, so re-sedation may occur after an apparently successful resuscitation. Take-home naloxone should be offered to any patient at risk, and to family members.
Stimulants, nicotine and other substances
| Substance | Presentation | Treatment |
|---|---|---|
| Cocaine and amphetamines | Intoxication with tachycardia, hypertension, hyperthermia, chest pain, seizures, psychosis with paranoid delusions and stereotypy; a crash with hypersomnia, depression and craving; and a persistent depressive state in chronic use | Supportive care with cooling, fluids and monitoring; benzodiazepines for agitation; antipsychotics for psychosis; psychiatric follow-up for the depressive phase, in which suicide risk is high. There is no approved medication for dependence |
| Cannabis | Dependence with irritability and insomnia on withdrawal; anxiety and depersonalisation on intoxication; and a risk of psychosis with high-potency and early-onset use | Cognitive behavioural therapy and motivational interviewing; treat any psychosis with antipsychotics and advise cessation |
| Nicotine | Dependence with withdrawal on cessation, and mortality driven by cardiovascular disease and cancer | Nicotine replacement therapy, varenicline (a partial nicotinic agonist, the most effective single pharmacotherapy), or bupropion; combined with behavioural support and follow-up. Stop-smoking advice is one of the most cost-effective interventions in medicine |
| Benzodiazepines and Z-drugs | Dependence and withdrawal, with cross-tolerance to alcohol, so withdrawal can be dangerous and can overlap with alcohol withdrawal | Slow taper, often switching to an equivalent dose of diazepam which has a long half-life and smoother decline; do not stop abruptly; inpatient tapering where dependence is severe |
| Hallucinogens and novel psychoactive substances | Acute intoxication with hallucination, agitation and paraesthesia; hallucinogen persisting perception disorder rarely after heavy use | Supportive care; benzodiazepines for agitation; no specific pharmacotherapy for dependence, which is uncommon |
| Inhaled solvents | Acute intoxication with euphoria then drowsiness, ataxia, arrhythmia and risk of sudden death; chronic use causes cerebellar and pyramidal damage | Supportive care and harm reduction; specialist adolescent services |
Harm reduction and legal frameworks
Most deaths in opioid dependence are from overdose, and most harm from injection comes from the injection rather than the drug. Harm reduction — needle and syringe programmes, supervised consumption, take-home naloxone, hepatitis B and C screening and vaccination, HIV testing, wound care, and education on safer injection — reduces mortality and infection rates, and does not increase drug use. It is the clinical baseline for every patient who injects.
Compulsory detention for intoxication is a legal intervention under mental health or drugs legislation, and requires the same justification as any detention: a mental disorder of a nature or degree warranting it, necessity, and the absence of a less restrictive alternative, with the maximum available proportionality. Most jurisdictions provide for a period of short assessment for a person intoxicated to the point of danger, and that is the limit of what may be done without a full assessment. Work with the patient's capacity wherever capacity exists; assume capacity until shown absent, and record the reasons for any decision that capacity is absent.
Watch outLanguage is part of treatment in this field. 'Addict', 'junkie', 'abuser' and 'clean' as a synonym for abstinent all reduce engagement, and studies show they predict clinician attitudes and referral decisions. Use 'person with alcohol dependence', 'patient who injects drugs', 'in recovery', and 'negative drug screen' instead.
Common mistakes
Watch outGiving intravenous glucose to a hypoglycaemic, malnourished, intoxicated patient without parenteral thiamine. This is a preventable cause of Wernicke encephalopathy and Korsakoff syndrome, it is committed exactly when the patient is least able to report symptoms, and the correct order is thiamine first or simultaneously.
Watch outStopping benzodiazepines abruptly in a dependent patient. Benzodiazepine withdrawal causes seizures, and cross-tolerance with alcohol makes it the same dangerous pharmacology. Switch to diazepam and taper slowly, or admit for withdrawal.
Watch outAttributing the whole of a patient's presentation to alcohol, or refusing to treat the alcohol because there is psychiatric comorbidity. Psychiatric comorbidity is common, predicts worse outcome, and is often undertreated in patients with alcohol dependence; depression improves in many patients within weeks of abstinence, but untreated depression and suicidal ideation should not simply be waited out.
Check your understanding
A 54-year-old man with alcohol dependence is admitted with confusion and ataxia, and a blood glucose of 1.9 mmol/L is measured from the intravenous cannula. What comes first?
How does naloxone have a shorter half-life in clinical practice, and what does this mean for monitoring?
Why does alcohol withdrawal become more dangerous with successive detoxifications?
Summary and next
Alcohol and benzodiazepine withdrawal share GABA-A pharmacology and are the two reliably life-threatening withdrawal syndromes; opioids cause dependence and fatal overdose but a non-fatal withdrawal; stimulants produce a depressive crash and psychosis. Screening with the AUDIT and CAGE identifies the great majority of patients. Alcohol detoxification is an inpatient decision where seizures, delirium tremens or significant comorbidity are present, and relapse prevention combines pharmacotherapy with psychological and social work. Opioid substitution therapy, take-home naloxone and harm reduction are the mortality-reducing interventions in injection use, and language is part of the clinical method.
This lesson completes the twelve authored lessons of PSYT 306: the behavioural sciences (lessons 1 to 4), the foundations of classification and aetiology (lessons 5 and 6), the psychotic and mood disorders (lessons 7 to 9), and the anxiety, dissociative and substance use disorders (lessons 10 to 12). Still to be authored in the course spine: stress-related and personality disorders, child and adolescent disorders, psychological therapies and counselling, and psychological testing with psychiatric emergencies — each of which builds on what is now in place.
Multiple choice
At what point in alcohol withdrawal do withdrawal seizures typically occur?
Which is the correct order of treatment for a confused, malnourished, intoxicated patient who is hypoglycaemic?
A patient is found unconscious with pinpoint pupils and a respiratory rate of 4. What is the treatment of choice?
Which is the most effective single pharmacological treatment for smoking cessation?
Which statement about opioid substitution therapy is correct?